
Elanco Animal Health Incorporated
ELANNYSEHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$23.97
+$0.41 · +1.74%
Pre-market
$24.36
+$0.39 · +1.63%
Aug 24, 8:51 AM ET
ELAN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
35
Expensive
Momentum
52
Neutral
Sentiment
57
Mixed
Risk resilience
59
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteElanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jeffrey N. Simmons
- Listed since
- Sep 20, 2018
- Employees
- 9,650
Market position
Day range
Current $23.97
52-week range
Current $23.97
- Open
- $23.91
- Previous close
- $23.56
- Volume
- 4.75M
- 0.76× average
- Average volume
- 6.3M
- Average daily volume
- Market cap
- 11.97B USD
- Beta
- 1.69
- Market reference 1
- 50-day average
- $24.5388
- -2.32% below average
- 200-day average
- $23.6075
- +1.54% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 14.71B USD
- P/E (TTM)
- -58.46×
- P/B (TTM)
- 1.82×
- P/S (TTM)
- 2.38×
- EV / EBITDA
- 21.75×
- Earnings yield
- -2.07%
- Free cash flow yield
- 2.53%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 52.59%
- Operating margin
- 9.20%
- Net margin
- -3.96%
- Return on equity
- -3.54%
- Return on assets
- -1.74%
- Return on invested capital
- 2.13%
Financial health
- Debt / equity
- 0.59×
- Current ratio
- 2.17×
- Altman Z-score
- 1.38
- Piotroski F-score
- 5 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.72B USD | 4.44B USD | 4.42B USD | 4.41B USD | 4.76B USD |
| Cost of goods sold | 2.67B USD | 2.53B USD | 2.48B USD | 2.44B USD | 2.69B USD |
| Gross profit | 2.05B USD | 1.91B USD | 1.94B USD | 1.97B USD | 2.08B USD |
| Research and development | 368M USD | 344M USD | 327M USD | 321M USD | 369M USD |
| Selling, general, and administrative | 1.43B USD | 1.31B USD | 1.29B USD | 1.27B USD | 1.4B USD |
| Operating expenses | 1.8B USD | 1.66B USD | 1.61B USD | 1.59B USD | 1.77B USD |
| Interest income | 45M USD | — | — | — | — |
| Interest expense | 220M USD | 339M USD | 277M USD | 256M USD | 264M USD |
| Depreciation and amortization | 680M USD | 662M USD | 694M USD | 682M USD | 716M USD |
| Operating income | 252M USD | 251M USD | 326M USD | 384M USD | 304M USD |
| Net income | −232M USD | 338M USD | −1.23B USD | −78M USD | −483M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 82%
- 9 beats, 2 misses, 0 met estimates
- Average EPS surprise
- +16.42%
- 11 comparable reports
- Latest EPS result
- 0.34
- Estimate 0.27 · Beat by 26.30%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$28.67
19.61% upsideRating distribution
21 ratingsRecent analyst actions
ELAN news
ELAN peers
ETFs holding ELAN
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI419.94M0.02%2.3T USD0.03%$378.24+0.44%
iShares Core S&P Mid-Cap ETFIJH407.89M0.32%125.92B USD0.05%$76.77+0.52%
Vanguard Morningstar Small-Cap ETFVB302.64M0.16%183.4B USD0.03%$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR192.3M0.28%68.3B USD0.05%$249.18+0.68%
Vanguard Extended Market ETFVXF151.72M0.16%93.7B USD0.05%$245.53+0.82%
Invesco S&P MidCap Momentum ETFXMMO103.31M1.39%7.45B USD0.35%$157.09+0.08%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY86.18M0.32%26.72B USD0.23%$699.6+0.48%
iShares S&P Mid-Cap 400 Growth ETFIJK68.87M0.61%10.95B USD0.16%$115.45+0.37%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 419.94M
- Weight
- 0.02%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Core S&P Mid-Cap ETFIJH- Market value
- 407.89M
- Weight
- 0.32%
- AUM
- 125.92B USD
- Expense ratio
- 0.05%
- Price / 1D
- $76.77+0.52%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 302.64M
- Weight
- 0.16%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 192.3M
- Weight
- 0.28%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $249.18+0.68%
Vanguard Extended Market ETFVXF- Market value
- 151.72M
- Weight
- 0.16%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Invesco S&P MidCap Momentum ETFXMMO- Market value
- 103.31M
- Weight
- 1.39%
- AUM
- 7.45B USD
- Expense ratio
- 0.35%
- Price / 1D
- $157.09+0.08%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY- Market value
- 86.18M
- Weight
- 0.32%
- AUM
- 26.72B USD
- Expense ratio
- 0.23%
- Price / 1D
- $699.6+0.48%
iShares S&P Mid-Cap 400 Growth ETFIJK- Market value
- 68.87M
- Weight
- 0.61%
- AUM
- 10.95B USD
- Expense ratio
- 0.16%
- Price / 1D
- $115.45+0.37%
Continue in GoAI
Research ELANresearch.disclaimer











